A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes (Q79162285)
Jump to navigation
Jump to search
scientific article published on 12 September 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes |
scientific article published on 12 September 2006 |
Statements
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes (English)
Robert M Califf
Harvey D White
Elliott M Antman
Anatoly Langer
Kenneth W Mahaffey
SYNERGY Trial Investigators
Shaun G Goodman
Marc Cohen
Karen Pieper
Charles V Pollack
James Hoekstra
Jacques J Col
James J Ferguson
12 September 2006